Title |
Efficacy of ultra-short course chemotherapy for new smear positive drug susceptible pulmonary tuberculosis: study protocol of a multicenter randomized controlled clinical trial
|
---|---|
Published in |
BMC Infectious Diseases, June 2017
|
DOI | 10.1186/s12879-017-2505-7 |
Pubmed ID | |
Authors |
Mengqiu Gao, Jingtao Gao, Jian Du, Yuhong Liu, Yao Zhang, Liping Ma, Fengling Mi, Liang Li, Shenjie Tang, on behalf of the Trial Team |
Abstract |
Shortening the standard 6-month treatment for drug-susceptible pulmonary tuberculosis (DS-PTB) would be a major improvement for TB case management and disease control. We are conducting a randomized, open-label, controlled, non-inferiority trial involving patients with smear-positive, newly diagnosed DS-PTB cases nationwide to assess the efficacy and safety of two 4.5- month regimens in comparison to the standard 6-month WHO recommended regimen. The regimen used in one experiment group is a 4.5-month fluoroquinolone-containing regimen, which consists of full course of levofloxacin, isoniazid (H), rifampin (R), parazinamid (Z) and ethambutol (E). Regimen used in the second experiment group includes 4.5-month full course of H, R, Z, E with levofloxacin removed. Patients in the control group, receive H, R, Z and E for 2 months, followed by 4 months of H and R. The primary endpoint is treatment failure or relapse within 24 month after treatment completion. Results from this trial along with other studies will contribute to the science of constructing a shorter, effective and safe regiment for TB patients. The protocol has been registered on ClinicalTrials.gov on 2 September,2016 with identifier NCT02901288 . |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 42 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 8 | 19% |
Researcher | 4 | 10% |
Student > Bachelor | 3 | 7% |
Student > Doctoral Student | 3 | 7% |
Other | 2 | 5% |
Other | 7 | 17% |
Unknown | 15 | 36% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 14 | 33% |
Nursing and Health Professions | 6 | 14% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
Agricultural and Biological Sciences | 1 | 2% |
Biochemistry, Genetics and Molecular Biology | 1 | 2% |
Other | 2 | 5% |
Unknown | 16 | 38% |